38
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists

      review-article
      ehaa1044-aff1 , ehaa1044-aff2 , ehaa1044-aff3 , ehaa1044-aff4 , ehaa1044-aff5 , ehaa1044-aff6 , ehaa1044-aff7 , ehaa1044-aff8 , ehaa1044-aff9 , ehaa1044-aff10 , ehaa1044-aff11 , ehaa1044-aff12 , ehaa1044-aff13 , ehaa1044-aff14 , ehaa1044-aff15 , ehaa1044-aff14
      European Heart Journal
      Oxford University Press
      Coronary artery disease, Ischaemic heart disease, Menopausal hormone therapy, Female-specific risk factors, Hypertensive pregnancy disorders, Menopause, Transgender, Sexual health women

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Women undergo important changes in sex hormones throughout their lifetime that can impact cardiovascular disease risk. Whereas the traditional cardiovascular risk factors dominate in older age, there are several female-specific risk factors and inflammatory risk variables that influence a woman’s risk at younger and middle age. Hypertensive pregnancy disorders and gestational diabetes are associated with a higher risk in younger women. Menopause transition has an additional adverse effect to ageing that may demand specific attention to ensure optimal cardiovascular risk profile and quality of life. In this position paper, we provide an update of gynaecological and obstetric conditions that interact with cardiovascular risk in women. Practice points for clinical use are given according to the latest standards from various related disciplines ( Figure 1 ).

          Related collections

          Most cited references313

          • Record: found
          • Abstract: found
          • Article: found

          2018 ESC/ESH Guidelines for the management of arterial hypertension

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

            Summary Background Rigorous analysis of levels and trends in exposure to leading risk factors and quantification of their effect on human health are important to identify where public health is making progress and in which cases current efforts are inadequate. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a standardised and comprehensive assessment of the magnitude of risk factor exposure, relative risk, and attributable burden of disease. Methods GBD 2019 estimated attributable mortality, years of life lost (YLLs), years of life lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 87 risk factors and combinations of risk factors, at the global level, regionally, and for 204 countries and territories. GBD uses a hierarchical list of risk factors so that specific risk factors (eg, sodium intake), and related aggregates (eg, diet quality), are both evaluated. This method has six analytical steps. (1) We included 560 risk–outcome pairs that met criteria for convincing or probable evidence on the basis of research studies. 12 risk–outcome pairs included in GBD 2017 no longer met inclusion criteria and 47 risk–outcome pairs for risks already included in GBD 2017 were added based on new evidence. (2) Relative risks were estimated as a function of exposure based on published systematic reviews, 81 systematic reviews done for GBD 2019, and meta-regression. (3) Levels of exposure in each age-sex-location-year included in the study were estimated based on all available data sources using spatiotemporal Gaussian process regression, DisMod-MR 2.1, a Bayesian meta-regression method, or alternative methods. (4) We determined, from published trials or cohort studies, the level of exposure associated with minimum risk, called the theoretical minimum risk exposure level. (5) Attributable deaths, YLLs, YLDs, and DALYs were computed by multiplying population attributable fractions (PAFs) by the relevant outcome quantity for each age-sex-location-year. (6) PAFs and attributable burden for combinations of risk factors were estimated taking into account mediation of different risk factors through other risk factors. Across all six analytical steps, 30 652 distinct data sources were used in the analysis. Uncertainty in each step of the analysis was propagated into the final estimates of attributable burden. Exposure levels for dichotomous, polytomous, and continuous risk factors were summarised with use of the summary exposure value to facilitate comparisons over time, across location, and across risks. Because the entire time series from 1990 to 2019 has been re-estimated with use of consistent data and methods, these results supersede previously published GBD estimates of attributable burden. Findings The largest declines in risk exposure from 2010 to 2019 were among a set of risks that are strongly linked to social and economic development, including household air pollution; unsafe water, sanitation, and handwashing; and child growth failure. Global declines also occurred for tobacco smoking and lead exposure. The largest increases in risk exposure were for ambient particulate matter pollution, drug use, high fasting plasma glucose, and high body-mass index. In 2019, the leading Level 2 risk factor globally for attributable deaths was high systolic blood pressure, which accounted for 10·8 million (95% uncertainty interval [UI] 9·51–12·1) deaths (19·2% [16·9–21·3] of all deaths in 2019), followed by tobacco (smoked, second-hand, and chewing), which accounted for 8·71 million (8·12–9·31) deaths (15·4% [14·6–16·2] of all deaths in 2019). The leading Level 2 risk factor for attributable DALYs globally in 2019 was child and maternal malnutrition, which largely affects health in the youngest age groups and accounted for 295 million (253–350) DALYs (11·6% [10·3–13·1] of all global DALYs that year). The risk factor burden varied considerably in 2019 between age groups and locations. Among children aged 0–9 years, the three leading detailed risk factors for attributable DALYs were all related to malnutrition. Iron deficiency was the leading risk factor for those aged 10–24 years, alcohol use for those aged 25–49 years, and high systolic blood pressure for those aged 50–74 years and 75 years and older. Interpretation Overall, the record for reducing exposure to harmful risks over the past three decades is poor. Success with reducing smoking and lead exposure through regulatory policy might point the way for a stronger role for public policy on other risks in addition to continued efforts to provide information on risk factor harm to the general public. Funding Bill & Melinda Gates Foundation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sex differences in immune responses

              Males and females differ in their immunological responses to foreign and self-antigens and show distinctions in innate and adaptive immune responses. Certain immunological sex differences are present throughout life, whereas others are only apparent after puberty and before reproductive senescence, suggesting that both genes and hormones are involved. Furthermore, early environmental exposures influence the microbiome and have sex-dependent effects on immune function. Importantly, these sex-based immunological differences contribute to variations in the incidence of autoimmune diseases and malignancies, susceptibility to infectious diseases and responses to vaccines in males and females. Here, we discuss these differences and emphasize that sex is a biological variable that should be considered in immunological studies.
                Bookmark

                Author and article information

                Journal
                Eur Heart J
                Eur Heart J
                eurheartj
                European Heart Journal
                Oxford University Press
                0195-668X
                1522-9645
                07 March 2021
                25 January 2021
                25 January 2021
                : 42
                : 10 , Focus Issue on Interventional Cardiology
                : 967-984
                Affiliations
                [ehaa1044-aff1 ] Department of Cardiology, Director Women’s Cardiac Health Program, Radboud University Medical Center , Geert Grooteplein-Zuid 10, Route 616, 6525GA Nijmegen, The Netherlands
                [ehaa1044-aff2 ] St George's Hospitals NHS Trust University of London, Cranmer Terrace, London SW17 0RE , UK
                [ehaa1044-aff3 ] Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, via della Pisana, 235 Rome, Italy
                [ehaa1044-aff4 ] Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital , Vídeňská 800, 140 59 Prague 4, Czech Republic
                [ehaa1044-aff5 ] Department of Internal Cardiovascular Medicine, First Medical Faculty, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08 Prague 2 , Czech Republic
                [ehaa1044-aff6 ] Interventional Cardiology Unit, IRCCS San Raffaele Hospital , Olgettina Street, 60 - 20132 Milan (Milan), Italy
                [ehaa1044-aff7 ] Department of Obstetrics and Gynaecology, OLVG location West , Jan Tooropstraat 164, 1061 AE Amsterdam, The Netherlands
                [ehaa1044-aff8 ] Department Gynaecology, King's College Hospital , Denmark Hill, London SE5 9RS, UK
                [ehaa1044-aff9 ] Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust , M4:146 4th Floor William Leech Building, Newcastle upon Tyne NE2 4HH, UK
                [ehaa1044-aff10 ] Department of Sexology and Psychosomatic Gynaecology, Amsterdam University Medical Center, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
                [ehaa1044-aff11 ] Menopause Clinic, 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, 30 Panepistimiou Str., 10679  Athens, Greece
                [ehaa1044-aff12 ] Department Gynaecology, Chelsea and Westminster Hospital, NHS Foundation Trust , 69 Fulham Road London SW10 9NH, UK
                [ehaa1044-aff13 ] Department of Gynaecology, Queen Charlotte's & Chelsea and Westminster Hospitals, Imperial College , Du Cane Road, London W12 0HS, UK
                [ehaa1044-aff14 ] Department of Cardiology, National Heart & Lung Institute, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP , UK
                [ehaa1044-aff15 ] Bureau Gender PRO Vienna and Department of Obstetrics and Gynaecology, University Hospital St. Poelten-Lilienfeld, Probst Führer Straße 4 · 3100 St. Pölten , Austria
                Author notes
                Corresponding author. Tel: +31 24 3614533, Email: angela.maas@ 123456radboudumc.nl
                Author information
                https://orcid.org/0000-0001-5782-9926
                https://orcid.org/0000-0002-6868-4248
                https://orcid.org/0000-0003-2765-3821
                https://orcid.org/0000-0002-3505-9112
                https://orcid.org/0000-0002-9077-1567
                https://orcid.org/0000-0002-2330-1768
                https://orcid.org/0000-0003-2975-6971
                https://orcid.org/0000-0001-6084-9207
                https://orcid.org/0000-0003-1488-2668
                https://orcid.org/0000-0001-6662-1334
                https://orcid.org/0000-0003-4033-9618
                Article
                ehaa1044
                10.1093/eurheartj/ehaa1044
                7947184
                33495787
                ff9c6593-ca91-4b51-9214-16d52906b9b3
                © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 18 August 2020
                : 29 September 2020
                : 08 December 2020
                : 07 December 2020
                Page count
                Pages: 18
                Categories
                ESC Report
                AcademicSubjects/MED00200

                Cardiovascular Medicine
                coronary artery disease,ischaemic heart disease,menopausal hormone therapy,female-specific risk factors,hypertensive pregnancy disorders,menopause,transgender,sexual health women

                Comments

                Comment on this article